| Similar Articles |
|---|
 |
The Motley Fool
March 22, 2004
Alyce Lomax |
Walgreen's Green Quarter Investors take an earnings miss to heart. But the future looks good.   |
The Motley Fool
May 5, 2004
Mike Cianciolo |
CVS Prescribes Growth The soon-to-be leader of the drugstore market had a spectacular first quarter as a result of improved sales and margins, and CVS doesn't appear to be showing any signs of slowing down either, as the company continues to expand its business in both traditional and creative ways. |
The Motley Fool
January 5, 2004
Jeff Hwang |
Prescriptions Boost Walgreen Earnings and sales bumped by early flu season and improved non-pharmacy sales. |
The Motley Fool
July 6, 2004
Alyce Lomax |
Not Ready for Rite Aid Can the drugstore chain hold a candle to the competition? Its shares are trading at 22 times forward earnings, making it a seemingly less-than-advantageous time to place a bet on them. |
The Motley Fool
June 11, 2007
Mike Cianciolo |
Rite Aid's Generic Sales The drugstore chain gradually increases sales, and catches up to the big boys in one way. Investors, take note. |
The Motley Fool
April 8, 2004
Seth Jayson |
Rite Aid Wrings Out Profits Net store closings and comps increases bring black ink to the pharmacy's bottom line. |
The Motley Fool
January 4, 2008
Timothy M. Otte |
Drugstore Sales Droop in December The three major drugstore chains, Walgreen, CVS, and Rite Aid, all report soft sales for December. |
The Motley Fool
September 24, 2004
Seth Jayson |
Kick This Drug Habit Rite Aid offers slow sales and minuscule shareholder rewards. |
The Motley Fool
February 2, 2005
Alyce Lomax |
CVS's Shot in the Arm Buying the Eckerd drugstore chain from J.C. Penney was apparently a good move for CVS. It continues to benefit from the purchase, reporting positive earnings and beating analysts' expectations by a penny. |
The Motley Fool
August 15, 2005
Bobby Shethia |
Walgreen's Prescription for Success The drugstore chain's smart and steady growth makes it a good choice for investors. |
The Motley Fool
January 4, 2005
Seth Jayson |
Rite Aid Still Needs First Aid Sales keep slacking for this tough turnaround. This doesn't mean investors should necessarily jump ship. |
The Motley Fool
June 14, 2010
Rich Smith |
Is CVS' $2 Billion Buyback Good Medicine? Don't assume just because CVS is buying its stock, that this is a good idea. |
The Motley Fool
October 4, 2005
Seth Jayson |
Same Old Same-Store Story Reports from Walgreen and Rite Aid confirm the obvious. Investors will nearly always do better buying the best company in any given space. |
The Motley Fool
June 10, 2004
Alyce Lomax |
Summer Starts at CVS The drugstore company releases same-store sales results on the cusp of its Eckerd acquisition. |
The Motley Fool
June 25, 2004
Steven Mallas |
Rite Aid in the Shadows The first quarter for Rite Aid, the pharmaceutical retailer, shows a profit, but is it time to add this stock to your portfolio? |
The Motley Fool
January 3, 2005
Nathan Slaughter |
Walgreen Seeing Green Rivals CVS and Rite Aid have a bitter pill to swallow as Walgreen stays strong. While Walgreen's revenues were in line with forecasts, the stronger-than-expected bottom line has the stock gaining ground. |
The Motley Fool
July 7, 2004
Steven Mallas |
CVS's Bright Picture Send CVS your digital photos over the Net, pick them up the next day. While competitors are sure to follow suit, this still shows how intellegent and creative this drugstore blue chip can be. |
The Motley Fool
September 7, 2004
Seth Jayson |
Rejecting Rite Aid Shares of the drugstore chain droped 13%, and may prove to be a bargain if this is indeed a temporary slowdown and management can deliver more robust growth. |
The Motley Fool
April 4, 2007
Timothy M. Otte |
Walgreen's Comp Machine The drugstore operator steams through March with 8% comparable sales growth. The stock trades at a P/E of 24 times trailing-12-month earnings, about one-third higher than the average of all S&P 500 companies. |
The Motley Fool
March 28, 2005
Alyce Lomax |
A Cool Quarter for Walgreen Are second-quarter earnings putting a damper on Walgreen? |
The Motley Fool
April 9, 2007
Mike Cianciolo |
CVS: Continued Vigorous Sales The drugstore chain grows sales and itself in March. Investors, take note. |
The Motley Fool
August 4, 2004
Phil Wohl |
CVS's Prescription for Competition The national drugstore chain is looking to take advantage of increased size. |
The Motley Fool
July 5, 2005
Alyce Lomax |
Business As Usual at Walgreen Walgreen's same-store sales for June certainly don't disappoint. Investors might question whether the retail pharmacy can keep up the great work. |
The Motley Fool
May 9, 2005
Timothy M. Otte |
Flu Means All's Well for CVS Strong comp sales and benefits from the Eckerd acquisition drive CVS to a solid first quarter. Investors, take note. |
The Motley Fool
October 2, 2007
Lawrence A. Rothman |
Can the Right Prescription Heal Walgreen? Walgreen is suffering from heightened competition, expenses rising more than 11%, and the company itself predicting its challenges will probably continue into the near future. |
The Motley Fool
April 13, 2007
Ryan Fuhrmann |
Rite Aid's Right-Size Ambitions If the retail pharmacy chain can improve its net margins, reduce debt, and smoothly integrate its latest acquisition, the stock's upside would be substantial. |
The Motley Fool
July 6, 2004
Steven Mallas |
Walgreen's Sunny Sales The retail pharmacy has a resplendently ruddy June, with comp sales increasing more than 10%. |
The Motley Fool
June 2, 2004
Alyce Lomax |
Walgreen's Mellow May Will the drugstore chain get a taste of its own medicine? |
The Motley Fool
March 11, 2004
Seth Jayson |
Dillard's Still Dragging Sales, earnings, and comps are down -- but the stock is up. Go figure. |
The Motley Fool
October 5, 2007
Timothy M. Otte |
CVS: Consistently Very Solid The drugstore giant scores a consistent sales increase in September, as it begins to capitalize on synergies from its CareMark acquisition. |
The Motley Fool
March 9, 2004
Alyce Lomax |
February Frenzy at CVS, Rite Aid The flu season's early end hasn't stopped drugstore retailers. |
The Motley Fool
February 12, 2004
Dave Marino-Nachison |
CVS Bags Big 2003 A strong year for the drugstore giant has spilled into January. |
The Motley Fool
February 20, 2004
Seth Jayson |
RadioShack Attack The electronics retailer exceeds expectations and raises guidance for 2004. |
The Motley Fool
July 29, 2011
Shubh Datta |
A Drug Retailer for Your Portfolio With a strong balance sheet, Walgreen looks like a good buy. |
The Motley Fool
April 19, 2004
Seth Jayson |
Lexmark Inks More Profits The printer maker lives up to its buzz and continues to increase earnings. |
The Motley Fool
April 13, 2004
Seth Jayson |
Yee-Haw! for Tractor Supply The purveyor of goods for the rural life exceeds estimates. |
The Motley Fool
September 14, 2006
Ryan Fuhrmann |
Playing Defense With the Drugstore Industry Retail pharmacy August sales trends help investors discern the leader in this appealing sector. |
The Motley Fool
July 6, 2007
Timothy M. Otte |
Drugstore Sales Remain Healthy The big four drugstore chains report higher comparable sales in June. Walgreen... CVS... Rite Aid... Long's... |
The Motley Fool
September 27, 2004
Phil Wohl |
Walgreen: Prescription for Success The leading drugstore retailer is leveraging prescription sales to produce record results. Fourth-quarter earnings grew to $0.32 per share, which was an 18% improvement over last year's $0.27. |
The Motley Fool
May 19, 2004
Mike Cianciolo |
Dick's Doldrums The sporting goods retailer had a solid quarter, so why did the stock drop? |
The Motley Fool
September 27, 2007
Ryan Fuhrmann |
Rite Aid Looks a Little Peaked Bigger doesn't necessarily mean better for the drugstore retailer; it has quite a bit of work to do to convince investors it can successfully manage the empire that it has acquired. |
The Motley Fool
May 3, 2004
Seth Jayson |
The Post's Educational Advantage Kaplan and company outpaced the The Washington Post's traditional media segments. |
The Motley Fool
December 21, 2007
Timothy M. Otte |
Walgreen Shapes Up for 2008 The drugstore chain reports lower expenses in the first quarter while pumping up sales. |
The Motley Fool
May 18, 2004
Seth Jayson |
Perky Days for J.C. Penney This cornerstone of the American mall is outrunning its rivals. |
The Motley Fool
March 8, 2005
Seth Jayson |
Rite Aid Wretched? Value investors may be interested in Rite Aid. |
The Motley Fool
October 31, 2008
Timothy M. Otte |
CVS Caremark Takes Care of Its Investors The drugstore giant continues to scoop up market share. |
The Motley Fool
August 19, 2004
Nathan Slaughter |
Dillard's Dullness The retailer tumbles after missing earnings estimates. |
The Motley Fool
September 26, 2006
Ryan Fuhrmann |
Jaw-Dropping Pill-Popping at Walgreen How much longer can investors count on Walgreen's stellar numbers? |
The Motley Fool
March 24, 2008
Timothy M. Otte |
Expecting More From Walgreen The drugstore giant has managed to beat analyst estimates two quarters in a row, but earnings are lagging sales growth, and growth is slowing too. |
The Motley Fool
January 13, 2004
Alyce Lomax |
CVS Fever Drug stores benefit from the flu bug, but for how much longer? |
